Jeito Capital Closes $1.2B Fund II to Back Breakthrough Biopharma…

Team S · 2026-04-15T14:16:40.000Z

Paris-based venture firm Jeito Capital has closed its second biopharma-focused fund at $1.2 billion (€1 billion), marking one of the largest raises for an independent European life sciences investor and signaling strong momentum in the global biotech funding landscape. The oversubscribed fund exceeded its original target, reflecting strong backing from institutional investors and reinforcing confidence in Jeito’s strategy of investing in high-impact clinical-stage biopharma companies. Founded with a patient-centric investment approach, Jeito Capital focuses on supporting companies developing breakthrough therapies for severe diseases with high unmet medical needs. The new fund will continue this strategy by investing in around 15 to 20 clinical-stage companies, primarily across Europe, targeting areas such as oncology, neurology, autoimmune diseases, and cardiometabolic conditions. With this latest close, Jeito has tripled its assets under management to approximately €1.6 billion, strengthening its position as a leading global investor in the biopharma sector. The fund is designed to provide significant capital up to €150 million per company enabling startups to progress through late-stage clinical development and accelerate the path to commercialization. This approach addresses a critical funding gap in Europe, where promising biotech companies often struggle to secure sufficient capital during advanced development stages. As the demand for innovative therapies continues to grow globally, Jeito Capital is positioning itself at the forefront of the biopharma ecosystem, combining deep scientific expertise with large-scale capital deployment to drive the next generation of medical breakthroughs.

Member Login Get Access

Jeito Capital Closes $1.2B Fund II to Back Breakthrough Biopharma… | Newnex